Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma

Affiliations

¹ Dana-Farber/Brigham and Women's Cancer Center, Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts (B.M.A.); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T.); Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts (L.T.).

Comment

Brian M Alexander et al. Neuro Oncol. 2015 May.

. 2015 May;17(5):765-6.

doi: 10.1093/neuonc/nov024.

¹ Dana-Farber/Brigham and Women's Cancer Center, Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts (B.M.A.); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T.); Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts (L.T.).

No abstract available

Comment on

Progression-free survival: too much risk, not enough reward?
Alexander BM, Trippa L. Alexander BM, et al. Neuro Oncol. 2014 May;16(5):615-6. doi: 10.1093/neuonc/nou041. Neuro Oncol. 2014. PMID: 24733851 Free PMC article. No abstract available.
Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma.
Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Han K, et al. Neuro Oncol. 2015 May;17(5):764-5. doi: 10.1093/neuonc/nov021. Epub 2015 Feb 26. Neuro Oncol. 2015. PMID: 25722425 Free PMC article. No abstract available.

1. Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. NeuroOncol. 2014;16:696–706. - PMC - PubMed
1. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708. - PMC - PubMed
1. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–722. - PubMed
1. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–1649. - PMC - PubMed
1. Tang PA, Bentzen SM, Chen EX, et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25:4562–4568. - PubMed